Hypoxia in Gliomas: Opening Therapeutical Opportunities Using a Mathematical-Based Approach

Adv Exp Med Biol. 2016;936:11-29. doi: 10.1007/978-3-319-42023-3_2.

Abstract

This chapter explores the use of mathematical models as promising and powerful tools to understand the complexity of tumors and their, frequently, hypoxic environment. We focus on gliomas, which are primary brain tumors derived from glial cells, mainly astrocytes and/or oligodendrocytes. A variety of mathematical models, based on ordinary and/or partial differential equations, have been developed both at the micro and macroscopic levels. The aim here is to describe in a quantitative way key physiopathological mechanisms relevant in these types of malignancies and to suggest optimal therapeutical strategies. More specifically, we consider novel therapies targeting thromboembolic phenomena to decrease cell invasion in high grade glioma or to delay the malignant transformation in low grade gliomas. This study has been the basis of a multidisciplinary collaboration involving, among others, neuro-oncologists, radiation oncologists, pathologists, cancer biologists, surgeons and mathematicians.

Keywords: Antithrombotics and cancer; Malignant transformation of low-grade gliomas; Mathematical models of hypoxia in tumors; Microscopic mathematical model of glioblastoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytes / drug effects
  • Astrocytes / pathology
  • Brain Neoplasms / blood supply
  • Brain Neoplasms / complications
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / metabolism
  • Cell Count
  • Cell Movement / drug effects
  • Cell Transformation, Neoplastic / drug effects
  • Fibrinolytic Agents / therapeutic use*
  • Glioma / blood supply
  • Glioma / complications
  • Glioma / drug therapy*
  • Glioma / metabolism
  • Humans
  • Lab-On-A-Chip Devices
  • Models, Statistical*
  • Neoplasm Grading
  • Neoplasm Invasiveness
  • Oligodendroglia / drug effects
  • Oligodendroglia / pathology
  • Thromboembolism / complications
  • Thromboembolism / pathology
  • Thromboembolism / prevention & control*
  • Tumor Hypoxia*
  • Tumor Microenvironment / drug effects
  • Venous Thrombosis / complications
  • Venous Thrombosis / pathology
  • Venous Thrombosis / prevention & control*

Substances

  • Fibrinolytic Agents